Despite a weak Q1, HIMS & Hers shows strong long-term potential due to its market share growth, partnerships, and expansion plans, leading to a 'hold' sentiment.
Source Post
The creator discusses HIMS & Hers (HIMS) Q1 earnings, noting that while revenue growth was only 4% and net...
Mo InvestsMay 12, 2026
The creator discusses HIMS & Hers (HIMS) Q1 earnings, noting that while revenue growth was only 4% and net income was poor, there are underlying positive trends. The company's partnership with Novo Nordisk for weight-loss drugs, strong market share growth, and expansion plans are highlighted as reasons for a long-term bullish outlook, with the creator planning to hold the stock until the 2030s.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.